- Home
- SGU vs XFOR Comparison
SGU vs XFOR Comparison
Compare SGU & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGU | XFOR |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | N/A | 45 |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.3M | 377.3M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | SGU | XFOR |
|---|---|---|
| Price | $12.88 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 22.1K | ★ 957.1K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,784,418,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.70 | ★ N/A |
| Revenue Growth | ★ 1.04 | N/A |
| 52 Week Low | $11.37 | $1.35 |
| 52 Week High | $13.53 | $4.83 |
Technical Indicators
Market Signals| Indicator | SGU | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 54.66 | 50.44 |
| Support Level | $12.33 | $3.50 |
| Resistance Level | $12.85 | $4.38 |
| Average True Range (ATR) | 0.27 | 0.26 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 73.89 | 25.62 |
Price Performance
Historical ComparisonAbout SGU Star Group L.P.
Star Group LP is a home heating oil and propane distributor and services provider with one reportable operating segment that principally provides heating related services to residential and commercial customers. It serves residential and commercial customers whose primary use is to heat their homes and buildings in the Northeast and Mid-Atlantic U.S. regions. The company derives the majority of revenue from Petroleum products, which consist of home heating oil and propane as well as diesel fuel and gasoline.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.